IP Library Patent Application 12051283
Patent Application
App. No. 12/051,283

PREVENTING OR REDUCING OXIDATIVE STRESS OR OXIDATIVE CELL INJURY

Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US None
App. No.
12/051,283
Abstract

A water-soluble cellulose derivative is useful for preventing or reducing oxidative stress or oxidative cell injury in tissues of an animal and in particular for regulating Stearoyl-CoA Desaturase-1 gene expression and/or ATPF1 gene expression in non-adipose tissues of the animal.

Claims (23)

1 . A method of regulating the expression of a gene related to mitochondrial oxidation pathways of tissues of an animal, which method comprises the step of administering to the animal an effective amount of a water-soluble cellulose derivative.

2 .- 4 . (canceled)

5 . The method of claim 1 wherein ATP synthase gene expression is regulated.

6 . The method of claim 1 wherein the animal is a mammal.

7 . The method of claim 1 wherein the cellulose derivative is a water-soluble C 1 -C 3 -alkyl cellulose, a water-soluble C 1 -C 3 -alkyl hydroxy-C 1-3 -alkyl cellulose, a water-soluble hydroxy-C 1-3 -alkyl cellulose, a water-soluble mixed hydroxy-C 1 -C 3 -alkyl cellulose, or a water-soluble mixed C 1 -C 3 -alkyl cellulose.

8 . The method of claim 1 wherein from 10 to 300 milligrams of water-soluble cellulose derivative per pound of mammal body weight is administered per day in the form of a pharmaceutical composition, food or food supplement.

9 .- 14 . (canceled)

15 . A method of regulating ATPAF1 gene expression in tissues of an animal, which method comprises the step of administering to the animal an effective amount of a water-soluble cellulose derivative.

16 . The method of claim 15 wherein ATPAF1 gene expression in non-adipose tissues of an animal is reduced.

17 . The method of claim 15 wherein ATPAF1 gene expression in non-adipose tissues of a mammal is reduced.

18 . The method of claim 15 wherein the cellulose derivative is a water-soluble C 1 -C 3 -alkyl cellulose, a water-soluble C 1 -C 3 -alkyl hydroxy-C 1-3 -alkyl cellulose, a water-soluble hydroxy-C 1-3 -alkyl cellulose, a water-soluble mixed hydroxy-C 1 -C 3 -alkyl cellulose, or a water-soluble mixed C 1 -C 3 -alkyl cellulose.

19 . The method of claim 15 wherein from 10 to 300 milligrams of water-soluble cellulose derivative per pound of mammal body weight is administered per day in the form of a pharmaceutical composition, food or food supplement.

20 .- 22 . (canceled)

23 . A method of preventing or reducing oxidative stress or oxidative cell injury in tissues of an animal, which method comprises the step of administering to the animal an effective amount of a water-soluble cellulose derivative.

24 . The method of claim 23 wherein oxidative stress or oxidative cell injury induced by fat in nutrition is prevented or reduced.

25 . The method of claim 23 wherein oxidative stress or oxidative cell injury in non-adipose tissues of a mammal is reduced.

26 . The method of claim 23 wherein oxidative stress or oxidative cell injury in the liver, pancreas, lungs, kidneys, brain, stomach or in muscles of a mammal is reduced.

27 . The method of claim 23 wherein the cellulose derivative is a water-soluble C 1 -C 3 -alkyl cellulose, a water-soluble C 1 -C 3 -alkyl hydroxy-C 1-3 -alkyl cellulose, a water-soluble hydroxy-C 1-3 -alkyl cellulose, a water-soluble mixed hydroxy-C 1 -C 3 -alkyl cellulose, or a water-soluble mixed C 1 -C 3 -alkyl cellulose.

28 . A method of preventing or treating a disease of an organ of an animal caused or facilitated by oxidative stress or oxidative cell injury in said organ, which method comprises the step of administering to the animal an effective amount of a water-soluble cellulose derivative.

29 . The method of claim 28 for preventing or treating a liver disease, a mitochondrial or metabolic disease, atherosclerosis, ischemic injury, an inflammatory disease, a cardiovascular disorder, a neurological disease, muscle damage or for the treatment of AIDS.

30 . The method of claim 29 wherein said animal is a human being.

31 . The method of claim 29 wherein the cellulose derivative is a water-soluble C 1 -C 3 -alkyl cellulose, a water-soluble C 1 -C 3 -alkyl hydroxy-C 1-3 -alkyl cellulose, a water-soluble hydroxy-C 1-3 -alkyl cellulose, a water-soluble mixed hydroxy-C 1 -C 3 -alkyl cellulose, or a water-soluble mixed C 1 -C 3 -alkyl cellulose.

32 .- 41 . (canceled)

Assignments (1)
CHANGE OF NAME Recorded Apr 1, 2011
From: DOW GLOBAL TECHNOLOGIES INC.
To: DOW GLOBAL TECHNOLOGIES LLC
Reel/Frame 026069/0393 →